Dementia is not a single disease. It is an umbrella term for a group of symptoms involving memory loss, impaired reasoning, and declining ability to manage daily life. Alzheimer’s disease is the most common cause of those symptoms, but it is one of several diseases that fall under the dementia umbrella. The confusion between the two terms is widespread and understandable, because doctors, patients, and even some medical literature use them almost interchangeably. But the distinction has real consequences for treatment, prognosis, and family planning.
Why the Distinction Matters in Practice
Think of dementia the way you might think of “heart disease.” Heart disease is a broad category that includes heart attacks, heart failure, arrhythmias, and valve disorders. Telling someone they have “heart disease” gives you the general picture but tells you almost nothing about which treatment will help. Dementia works the same way. Someone can develop dementia from Alzheimer’s disease, from a series of small strokes, from abnormal protein deposits called Lewy bodies, from damage to the brain’s frontal and temporal lobes, or from a combination of these. Each cause has its own biology, its own pattern of symptoms, and its own trajectory. A person with Lewy body dementia might hallucinate vividly in the early stages, while someone with Alzheimer’s is more likely to first notice trouble remembering recent conversations. A person with frontotemporal dementia might start behaving in socially inappropriate ways years before any obvious memory problems appear. When families hear only the word “dementia,” they miss the chance to understand what is actually happening and what lies ahead.
What Alzheimer’s Disease Does to the Brain
Alzheimer’s disease is defined by two hallmark changes in brain tissue: clumps of a protein fragment called amyloid-beta that form plaques outside nerve cells, and twisted fibers of a protein called tau that form tangles inside them.1PubMed Central. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis These two features have been recognized since the early twentieth century, and they remain central to how the disease is diagnosed and studied today.2PubMed. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s The plaques and tangles gradually destroy synapses and kill neurons, typically starting in regions of the brain involved in forming new memories and then spreading outward. That is why short-term memory loss is usually the earliest and most prominent symptom.
Modern diagnostic criteria now recognize Alzheimer’s as a spectrum rather than a single stage. There is a preclinical phase where plaques and tangles are accumulating but the person has no symptoms, a stage of mild cognitive impairment where problems are noticeable but the person can still function independently, and finally the dementia stage where daily life requires increasing support.3PubMed Central. Distinguishing Alzheimer’s disease from other major forms of dementia Biomarkers, including tests for amyloid and tau in spinal fluid or on brain scans, have made it possible to detect the disease before symptoms become severe, though these tools are still far more common in research settings than in a typical doctor’s office.
Vascular Dementia and the Overlap Problem
Vascular dementia is the second most common form and arises from impaired blood flow to the brain, often due to strokes or chronic small-vessel disease.4PubMed. Similarities between Alzheimer’s disease and vascular dementia In theory, the distinction sounds clean: Alzheimer’s is about plaques and tangles, vascular dementia is about blood supply. In practice, the two share so many features that separating them in a living patient can be genuinely difficult. Both can cause brain shrinkage in the temporal lobes, both can damage the hippocampus (the brain’s memory hub), and both produce overlapping patterns of memory loss and confusion.5PubMed Central. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease
Vascular dementia sometimes progresses in a stepwise fashion, with sudden declines following each new stroke, while Alzheimer’s tends to be a slower, more gradual slide. But that textbook distinction does not hold for everyone. Researchers have increasingly described dementia in older adults as a continuum, with pure Alzheimer’s at one end, pure vascular dementia at the other, and a large gray zone of “mixed” pathology in between that may actually represent the majority of cases.4PubMed. Similarities between Alzheimer’s disease and vascular dementia
Lewy Body and Frontotemporal Dementia
Lewy body dementia involves abnormal deposits of a protein called alpha-synuclein inside neurons. It shares features with both Alzheimer’s and Parkinson’s disease, which makes it especially tricky to diagnose. People with Lewy body dementia often experience visual hallucinations early on, fluctuating alertness from one hour to the next, and movement problems that resemble Parkinson’s. Memory loss is present but tends to be less prominent at the start compared to Alzheimer’s. The cognitive profile leans more toward problems with attention, spatial reasoning, and executive function than toward the pure memory deficit that defines early Alzheimer’s.6Journal of Neurology, Neurosurgery & Psychiatry. Differential memory and executive functions in demented patients with Parkinson’s and Alzheimer’s disease
Frontotemporal dementia, by contrast, often strikes younger adults, sometimes in their fifties or even forties. The behavioral variant is the most common form, and its early symptoms can be mistaken for a psychiatric disorder rather than a neurological one: loss of empathy, compulsive behaviors, poor impulse control, or a flat indifference to social norms. Memory may be relatively preserved at first, which is why frontotemporal dementia is sometimes confused with Alzheimer’s or vice versa. One review noted that despite very different underlying clinical patterns, the overlap in cognitive and behavioral features between the two can lead to misdiagnosis or delayed diagnosis.7PubMed Central. Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia? Review of Key Points Toward an Accurate Clinical and Neuropsychological Diagnosis
Mixed Dementia Is Probably More Common Than Most People Realize
When autopsy studies examine the brains of older adults who had dementia, they frequently find more than one type of pathology. A person diagnosed with Alzheimer’s during life might also have significant vascular damage, or Lewy body deposits alongside their plaques and tangles. This coexistence of pathologies is called mixed dementia, and it may represent the most common form of cognitive decline in later life.8PubMed Central. Oxidative Stress as a Central Mechanistic Bridge Between Alzheimer’s and Vascular Pathologies in Mixed Dementia: Emerging Evidence and Therapeutic Perspectives The most frequent combination is Alzheimer’s and vascular disease together, and researchers are finding that vascular damage can actually accelerate the Alzheimer’s process rather than just piling on separately.9PubMed Central. The pathophysiology of mixed Alzheimer’s disease and vascular dementia
Mixed dementia complicates everything from diagnosis to treatment. If a person’s cognitive decline is partly driven by vascular disease, then managing blood pressure and cardiovascular health could slow things down in a way that purely targeting amyloid would not. The problem is that clinicians often cannot tell during life exactly how much of the problem is Alzheimer’s and how much is vascular. This is an area where the neat categories doctors use start to break down.
When It Is Not Dementia at All
Not all cognitive decline is irreversible. Depression, vitamin B12 deficiency, thyroid disorders, infections, and even certain medications can cause symptoms that closely resemble dementia but are potentially treatable or reversible.10PubMed Central. What do we know about pseudodementia? This phenomenon, sometimes called pseudodementia, is one of the strongest reasons to seek a thorough evaluation rather than accepting a vague “dementia” label. Depression is perhaps the most well-known mimic: older adults with severe depression can appear confused, forgetful, and unable to concentrate in ways that look indistinguishable from early dementia.11PubMed Central. Pseudodementia, pseudo-pseudodementia, and pseudodepression
Getting the diagnosis right here has enormous stakes. A person whose cognitive symptoms stem from an untreated thyroid condition may recover fully with hormone replacement. A person whose symptoms stem from depression may improve dramatically with antidepressants or therapy. Neither will benefit from being placed on Alzheimer’s medications and told to plan for progressive decline. This is another reason the “dementia versus Alzheimer’s” question matters so much in practice: the umbrella is wide enough to include conditions that have no business being treated the same way.
Genetics and Family Risk
Families often want to know whether a relative’s diagnosis means they are next. The genetics of dementia vary considerably by type. For Alzheimer’s, the strongest known genetic risk factor is a gene called APOE. The ε4 version of this gene significantly increases Alzheimer’s risk and may affect more than half of all cases, while the ε2 version appears protective compared to the common ε3 variant.12PubMed Central. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies But carrying ε4 is not a death sentence; plenty of people with one or even two copies never develop the disease.
A small number of families carry mutations that cause early-onset Alzheimer’s with near certainty, typically before age 65. These mutations, in genes known as APP, PSEN1, and PSEN2, follow a dominant inheritance pattern, meaning each child of an affected parent has a 50% chance of inheriting the mutation and a lifetime dementia risk above 95%.13The Lancet. Genetics of dementias These families are rare, however. For the far more common late-onset forms, the genetics are messier: many small-effect genetic variations interact with each other and with lifestyle factors. Having a parent with late-onset Alzheimer’s roughly doubles your lifetime risk to about 20%, compared with around 10% in the general population.13The Lancet. Genetics of dementias
Frontotemporal dementia has its own set of genes, including MAPT, GRN, and C9ORF72, and some of these also follow dominant inheritance patterns. Vascular dementia, on the other hand, is shaped far more by cardiovascular risk factors than by a single gene. The genetic story, in short, depends entirely on which type of dementia is under discussion.
How Treatments Differ by Type
Treatment options reinforce why the specific diagnosis matters. Alzheimer’s can be treated with cholinesterase inhibitors, the drug memantine, and newer anti-amyloid immunotherapies that modestly slow cognitive and functional decline in people with mild impairment or early-stage Alzheimer’s dementia.14JAMA Internal Medicine. Dementia Prevention and Treatment: A Narrative Review The cholinesterase inhibitors and memantine may also help people with Lewy body dementia, Parkinson’s disease dementia, vascular dementia, and dementia from traumatic brain injury, though the evidence is generally strongest for Alzheimer’s.14JAMA Internal Medicine. Dementia Prevention and Treatment: A Narrative Review
The new anti-amyloid drugs, which target and remove amyloid plaques from the brain, are specifically designed for Alzheimer’s and would not be expected to help someone whose dementia has a purely vascular or frontotemporal cause. Giving an anti-amyloid drug to someone with frontotemporal dementia would be like giving a blood thinner to someone whose heart problem is a valve defect. It targets the wrong mechanism. Meanwhile, vascular dementia often responds best to aggressive management of cardiovascular risk factors: controlling blood pressure, treating diabetes, lowering cholesterol, and quitting smoking. These measures are good general advice, but for vascular dementia they are arguably the single most impactful intervention available.
Life Expectancy and Disease Course
Prognosis varies across dementia types, though all of them shorten life expectancy. A large systematic review found that the average survival time from Alzheimer’s disease onset was about seven and a half years, with roughly six years after diagnosis.15The Lancet Healthy Longevity. Mortality rates and survival in people with dementia: a systematic review and meta-analysis Non-Alzheimer’s dementias were associated with a higher risk of death and shorter survival after diagnosis, by roughly a year on average, though the differences among vascular dementia, Lewy body dementia, and frontotemporal dementia were not statistically distinguishable from each other.15The Lancet Healthy Longevity. Mortality rates and survival in people with dementia: a systematic review and meta-analysis
A Norwegian study offered a more granular picture. At age 70, men with vascular dementia or Lewy body dementia lost about ten years of life compared to the general population, while men with Alzheimer’s lost about nine years. Women fared slightly differently: those with vascular dementia or Lewy body dementia lost nearly thirteen years, while those with Alzheimer’s lost about ten.16PLOS ONE. Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway Factors associated with worse survival included being male, having other chronic conditions, lower cognitive function at diagnosis, and greater difficulty with daily activities.
Modifiable Risk Factors Apply Across the Board
One of the more hopeful developments in dementia research is the growing list of risk factors that are at least partially within your control. Observational studies have linked midlife high blood pressure, high cholesterol, obesity, diabetes, smoking, physical inactivity, depression, and low educational attainment to higher dementia risk.17Nature Reviews Neurology. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease These factors are especially relevant to vascular dementia but appear to matter for Alzheimer’s risk as well, possibly because vascular health and amyloid clearance are more intertwined than researchers once thought.
Mild cognitive impairment, the transitional stage between normal aging and dementia, is another window where intervention might help. Not everyone with mild cognitive impairment progresses to dementia. Identifying and managing risk factors during this stage is an active area of research, with the goal of slowing or preventing that transition.18PubMed Central. Risk factors for the progression of mild cognitive impairment to dementia
How Sleep Fits Into the Picture
Sleep disturbance is both a symptom and a suspected contributor to dementia. The brain has a waste-clearance system, sometimes called the glymphatic system, that is most active during sleep. This system flushes out metabolic byproducts, including amyloid-beta and tau, the very proteins that accumulate in Alzheimer’s disease.19PubMed Central. Glymphatic failure as a final common pathway to dementia The clearance process appears to peak during deep, slow-wave sleep, when the spaces between brain cells expand and cerebrospinal fluid flows more freely through brain tissue.20PubMed Central. Sleep‐Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for Alzheimer’s Pathophysiology
As people age, both sleep quality and glymphatic function decline, raising the question of whether poor sleep in middle and later life directly accelerates the brain changes that lead to dementia. Experimental work shows that sleep disruption impairs clearance of amyloid and tau, while aging and vascular dysfunction further degrade the system.20PubMed Central. Sleep‐Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for Alzheimer’s Pathophysiology This line of research is still developing, but it has drawn attention to sleep as a potentially modifiable factor, not just in Alzheimer’s disease specifically but in neurodegeneration more broadly.
Caregiver Burden Depends on the Type
The impact on families is not uniform across dementia types. Caregivers of people with Lewy body dementia, frontotemporal dementia, and mixed dementia consistently report a higher burden than caregivers of people with Alzheimer’s disease.21PubMed Central. A Comparison of Caregiver Burden for Different Types of Dementia: An 18-Month Retrospective Cohort Study The reasons are intuitive once you know the symptoms. Lewy body dementia often brings hallucinations, rapid fluctuations in alertness, and movement difficulties on top of cognitive decline. Frontotemporal dementia can involve dramatic personality changes, loss of empathy, and socially disruptive behavior. Research comparing the behavioral variant of frontotemporal dementia to Alzheimer’s found that caregivers of the former reported a higher presence and severity of neuropsychiatric symptoms and greater distress.22Dement Geriatr Cogn Disord. Neuropsychiatric Symptoms, Caregiver Burden and Distress in Behavioral-Variant Frontotemporal Dementia and Alzheimer’s Disease
Alzheimer’s disease, for all its devastation, tends to progress more gradually and predictably. Caregivers can often build routines around the slow decline. When the dementia type involves unpredictable behavior, hallucinations, or sudden shifts in functioning, the daily caregiving experience becomes harder to manage even at similar levels of cognitive impairment.
Diagnostic Delays and Who Gets Missed
Getting the right diagnosis is harder for some groups than others. A study analyzing U.S. claims data found that Hispanic patients experienced an estimated average diagnostic delay of nearly 44 months, compared with about 31 months for non-Hispanic white patients. Non-Hispanic Black patients fell in between, at about 35 months.23PubMed Central. Dementia Diagnosis Disparities by Race and Ethnicity Hispanic patients were also significantly more likely to have a missed or delayed clinical diagnosis. By the time these patients received a formal diagnosis, they had poorer cognitive function and more functional limitations than their white counterparts at the same diagnostic milestone.
These disparities have cascading consequences. A delayed diagnosis means less time on treatments that are most effective early, fewer months to plan legally and financially while the person still has capacity, and more crisis-driven care. The causes are complex and include differences in access to specialty care, cultural framing of memory loss as normal aging, language barriers during cognitive testing, and potential biases in clinical assessment. For anyone concerned about a family member’s cognition, the practical takeaway is that a thorough workup from a specialist is worth pursuing, and worth pushing for, even if the first clinician dismisses the concern.